ALISON SMITH: Open Payments
NPI 1992223739 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$549 in 23 payments from 12 companies in 2025. Trend: 2023 $243 · 2024 $270 · 2025 $549
Food & beverage: $549
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $157 |
| Mallinckrodt Hospital Products Inc. | 4 | $90 |
| Novo Nordisk Inc | 4 | $69 |
| Novartis Pharmaceuticals Corporation | 2 | $51 |
| Fresenius USA Marketing, Inc. | 2 | $44 |
| SCPHARMACEUTICALS INC. | 2 | $36 |
| AKEBIA THERAPEUTICS INC | 1 | $20 |
| Calliditas Therapeutics US Inc. | 1 | $20 |
| ABBVIE INC. | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $16 |
Products named: LOKELMA, ACTHAR, FARXIGA, Ozempic, VELPHORO, FUROSCIX, Vanrafia, Fabhalta.
Industry payments across LA — which companies pay providers there.
